Literature DB >> 323290

Influence of a deficiency of the second component of complement on the bactericidal activity of neutrophils in vitro.

J E Repine, C C Clawson, P S Friend.   

Abstract

Serum from three patients with a complete, selective deficiency of the second component of complement (C2) did not promote optimal killing of Staphylococcus aureus, 502A by neutrophilic polymorphonuclear leukocytes (PMN) in vitro. The addition of C2 reagent or the presence of heat-stable opsonin in the C2-deficient serum corrected the defective killing of S. aureus that was observed with patient or control PMN. PMN from the patients or control subjects killed bacteria with equal efficiency under conditions of optimal opsonization (normal pooled serum). However, twice-washed control PMN were better than patient PMN in killing S. aureus under circumstances of suboptimal opsonization (C2-deficient serum, heated C2-deficient serum, heated normal pooled serum, or no replacement of serum). The latter finding was due to residual C2 on the surface of twice-washed control cells. As repeated washing of control PMN progressively removed cell-associated C2, the staphylocidal effectiveness of the control RMN decreased to the level of patient PMN. In contrast to the findings with S. aureus, triply-washed PMN from patients or controls killed normal numbers of Escherichia coli, ON2, in C2-deficient serum.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 323290      PMCID: PMC372288          DOI: 10.1172/JCI108702

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Quantitation of maximal bactericidal capability in human neutrophils.

Authors:  C C Clawson; J E Repine
Journal:  J Lab Clin Med       Date:  1976-08

2.  Opsonic activity in human serum deficient in C2.

Authors:  F R Johnson; V Agnello; R C Williams
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

3.  Hereditary C2 deficiency with some manifestations of systemic lupus erythematosus.

Authors:  V Agnello; M M De Bracco; H G Kunkel
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

4.  Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS).

Authors:  D C Morrison; L F Kline
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

5.  Deficiency of the second component of complement (C2) with chronic vasculitis.

Authors:  P Friend; J E Repine; C C Clawson; A F Michael
Journal:  Ann Intern Med       Date:  1975-12       Impact factor: 25.391

6.  Inherited deficiency of the second component of complement. Rheumatic disease associations.

Authors:  D Glass; D Raum; D Gibson; J S Stillman; P H Schur
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

7.  Inherited C2 deficiency and systemic lupus erythematosus: studies on a family.

Authors:  C K Osterland; L Espinoza; L P Parker; P H Schur
Journal:  Ann Intern Med       Date:  1975-03       Impact factor: 25.391

8.  Effects of phorbol myristate acetate on the metabolism and ultrastructure of neutrophils in chronic granulomatous disease.

Authors:  J E Repine; J G White; C C Clawson; B M Holmes
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

9.  Heat labile opsonins to pneumococcus. I. Participation of complement.

Authors:  M R Smith; W B Wood
Journal:  J Exp Med       Date:  1969-12-01       Impact factor: 14.307

10.  The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors.

Authors:  R B Johnston; M R Klemperer; C A Alper; F S Rosen
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  15 in total

1.  The effect of phorbol myristate acetate on the metabolism and ultrastructure of human alveolar macrophages.

Authors:  J R Hoidal; J E Repine; G D Beall; F L Rasp; J G White
Journal:  Am J Pathol       Date:  1978-06       Impact factor: 4.307

2.  Effect of staphylococcal iron content on the killing of Staphylococcus aureus by polymorphonuclear leukocytes.

Authors:  J E Repine; R B Fox; E M Berger; R N Harada
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

3.  Inhibition of human neutrophil oxidative metabolism and degranulation in vitro by nitroblue tetrazolium and vitamin E.

Authors:  J E Repine; G Rao; G D Beall; J G White
Journal:  Am J Pathol       Date:  1978-03       Impact factor: 4.307

4.  Hereditary C2 deficiency and systemic lupus erythematosus associated with severe glomerulonephritis.

Authors:  J L Roberts; M M Schwartz; E J Lewis
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

5.  Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes.

Authors:  P K Peterson; B J Wilkinson; Y Kim; D Schmeling; P G Quie
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

6.  Recurrent pyogenic infections in individuals with absence of the second component of complement.

Authors:  H A Sampson; A M Walchner; P J Baker
Journal:  J Clin Immunol       Date:  1982-01       Impact factor: 8.317

7.  Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

8.  Bacillus Calmette-Guérin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro.

Authors:  V B Antony; S A Sahn; A C Antony; J E Repine
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

9.  N,N'-dimethylthiourea dioxide formation from N,N'-dimethylthiourea reflects hydrogen peroxide concentrations in simple biological systems.

Authors:  W E Curtis; M E Muldrow; N B Parker; R Barkley; S L Linas; J E Repine
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

10.  Production of C2 by human alveolar macrophages.

Authors:  S K Ackerman; P S Friend; J R Hoidal; S D Douglas
Journal:  Immunology       Date:  1978-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.